Tue, Jan 27, 2015, 9:47 AM EST - U.S. Markets close in 6 hrs 13 mins

Recent

% | $
Quotes you view appear here for quick access.

Becton, Dickinson and Company Message Board

  • ivguru ivguru Jan 9, 2009 2:50 PM Flag

    BDX - Dominant Market Player In A Shrinking Market

    Please tell me how BD is going to sell more of its products or even maintain its current sales estimates in 2009?


    In today's new;


    "Crozer-Keystone Health to cut 400 jobs


    Crozer-Keystone Health System (Springfield, PA) is eliminating 400 jobs, starting this week, and is also discussing wage adjustments. Fewer than 400 people will be laid off because of a hiring freeze that has been in effect for several months. The system currently employs 7,000 people at five hospitals. The layoffs will include managers and non managers as well as union and nonunion workers. Crozer-Keystone cited a drop in revenue due to a decline in inpatient admissions and outpatient visits and an increase in patients who do not pay their bills."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Seems like apples and oranges to me. Healthcare as a sector is not immune to the recession. Hill-rom is suffering, for instance, because hospitals aren't buying new beds.

      But when people need a shot, they're gonna get a shot. They don't need to be in a hospital to get one. BDX profits off of cost-cutting trends towards outpatient care.

      And then there's diabetes. We ain't getting skinnier, and BDX is gonna be right there when we need that insuline injection.

      My understanding is that Crozer-Keystone is a hospital system. Cutting jobs doesn't seem like it'll have any effect on BDX, in the short term or long term.

    • The only thing that's shrinking is the share price of RVP.

      • 1 Reply to sane1here
      • Boy how'd you catch me???

        As IVGURU, I use the this name to research trends and post questions. I study an unusual collapse I feel is inevitable and see if anyone can prove me wrong. I warn the innocent and answer questions. For those who have read my warnings, I'm okay with that and hope you buy plenty of this stock. Just don't use this board to damage others and artifically lift this company. I'm brave enough to offer a contrary opinion where others are mindlessly cheerleading this stock up with no real basis other than its a medical stock and have hope its refuge. I've supported all my statements with fact. See my early posts about industry awareness of MRSA accomplished by GeneOhm is damaging to BD's own routine needle sales.

        AND THEN I log in as vanashingpoint then mindlessly support a syringe company that can't sell its syringe because its 3 times the cost, has no luer lock so it can't be used for anything except vaccine delivery.

        My motive is that I’m your friend in regards to BDX. This link will explain better what I mean by a friend.

        http://www.youtube.com/watch?v=MfL7STmWZ1c

    • I'm just wondering what motive ivguru and vanishpoint have to continually post messages trying to downgrade this wonderful company.

      First of all. They are one in the same. They think they've fooled us. lol

      Second of all. They are obviously invested heavily in a stock that has gotten beat up and are trying to compare BDX with that stock. Apples and Oranges sir.

      I've just added these two (one) to my ignore list. I think if you're an investor in BDX and would like to have honest discussions concering this stock that you do the same.

    • I agree. ivguru is absolutely right.

      BDX has never won any ECRI awards. RVP has been awarded top ratings from ECRI.

      Safetylok has actually been judged to INCREASE the chances for an accidental needlestick.

 
BDX
142.31-1.18(-0.82%)9:47 AMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.